Table 1 Characteristics of patients by experience with adverse event during DR-TB treatment (n = 149)
Adverse event not reported (n = 91) | Patient-reported adverse event (n = 58) | Total (n = 149) | |
|---|---|---|---|
n (%) | n (%) | n (%) | |
Sex | |||
Male | 47 (51.6%) | 35 (60.3%) | 82 (55.0%) |
Female | 44 (48.4%) | 23 (39.7%) | 67 (45.0%) |
Age at treatment initiation (years) | |||
Median (IQR) | 36 (29–44) | 35 (29–42) | 36 (29–43) |
18–35 | 45 (49.5%) | 29 (50%) | 74 (49.7%) |
≥ 35 | 46 (50.5%) | 29 (50%) | 75 (50.3%) |
Education | |||
Secondary school and higher | 86 (94.5%) | 49 (84.5%) | 135 (90.6%) |
Primary school or less | 5 (5.5%) | 9 (15.5%) | 14 (9.4%) |
Employment Status | |||
Unemployed | 47 (51.6%) | 38 (65.5%) | 85 (57.0%) |
Employed | 43 (47.3%) | 20 (34.5%) | 63 (42.3%) |
Missing/unknown | 1 (1.1%) | 0 (0%) | 1 (0.7%) |
Resistance Pattern | |||
MDR-TB (RIF and INH resistant) | 22 (24.2%) | 10 (17.2%) | 32 (21.5%) |
RIF resistant by Xpert MTB/RIF | 22 (24.2%) | 16 (27.6%) | 38 (25.5%) |
RIF mono-resistant (INH sensitive) | 39 (42.9%) | 28 (48.3%) | 67 (45.0%) |
Missing | 8 (8.8%) | 4 (6.9%) | 12 (8.1%) |
HIV Status | |||
HIV negative | 18 (19.8%) | 9 (15.5%) | 27 (18.1%) |
HIV positive | 69 (75.8%) | 47 (81.0%) | 116 (77.9%) |
HIV positive and on ART | 60 (87.0%) | 34 (72.3%) | 94 (81.0%) |
HIV positive not on ART | 9 (13.0%) | 13 (36.2%) | 22 (19.0%) |
Unknown | 4 (4.4%) | 2 (3.5%) | 6 (4.0%) |
Baseline CD4 (cells/mm3)# | |||
< 50 | 23 (31.5%) | 9 (18.4%) | 32 (26.2%) |
51–250 | 21 (27.8%) | 22 (44.9%) | 43 (35.3%) |
> 250 | 22 (30.1%) | 14 (28.6%) | 36 (29.5%) |
Missing | 7 (69.6%) | 4 (8.2%) | 11 (9.0%) |
DR-TB regimen | |||
Standard long-coursea | 61 (67.0%) | 31 (53.4%) | 92 (61.8%) |
Individualized long-courseb | 17 (18.7%) | 16 (27.6%) | 33 (22.1%) |
Standard short-coursec | 9 (9.9%) | 6 (10.3%) | 15 (10.1%) |
Individualized short-coursed | 4 (4.4%) | 5 (8.6%) | 9 (6.0%) |
Duration of DR-TB treatment (months) | |||
≤ 6 months | 37 (40.7%) | 29 (50.0%) | 66 (44.3%) |
> 6 months | 54 (59.3%) | 29 (50.0%) | 83 (55.7%) |
Duration of ART (months)& | |||
≤ 6 months | 9 (15.0%) | 5 (14.7%) | 14 (14.9%) |
> 6 months | 44 (73.3%) | 23 (67.6%) | 67 (71.3%) |
Missing | 7 (11.7%) | 6 (17.6%) | 13 (13.8%) |
Diabetes | |||
No | 67 (73.6%) | 42 (72.4%) | 109 (73.2%) |
Yes | 4 (4.4%) | 2 (3.5%) | 6 (4.0%) |
Missing | 20 (22.0%) | 14 (24.1%) | 34 (22.8%) |
Anaemia | |||
None or mild (Hb ≥11.0 g/dL) | 46 (50.5%) | 18 (31.0%) | 64 (43%) |
Moderate (8–10.9 g/dL) or severe (< 8 g/dL) | 13 (14.3%) | 13 (22.4%) | 26 (17.4%) |
Missing | 32 (35.2%) | 27 (46.6%) | 59 (39.6%) |
Weight at treatment initiation (kg) | |||
< 50 kg | 19 (20.9%) | 18 (31.0%) | 37 (24.8%) |
≥ 50 kg | 65 (71.4%) | 38 (65.5%) | 103 (69.1%) |
Missing | 7 (7.7%) | 2 (3.4%) | 9 (6%) |
Referring Facility | |||
Outpatient | 62 (68.1%) | 38 (65.5%) | 100 (67.1%) |
Inpatient | 29 (31.9%) | 20 (34.5%) | 49 (32.9%) |
Patient Category | |||
New | 52 (57.1%) | 38 (65.5%) | 90 (60.4%) |
Previously treated | 23 (25.3%) | 13 (22.4%) | 36 (24.2%) |
Missing | 16 (17.6%) | 7 (12.1%) | 23 (15.4%) |
TB Type | |||
PTB and EPTB or EPTB only | 14 (15.4%) | 10 (17.2%) | 24 (16.1%) |
PTB and not reported | 77 (84.6%) | 48 (82.8%) | 125 (83.9%) |
Smear Microscopy | |||
Negative | 57 (62.6%) | 42 (72.4%) | 99 (66.4%) |
Positive | 17 (18.7%) | 9 (15.5%) | 26 (17.4%) |
Unknown | 17 (18.7%) | 7 (12.1%) | 24 (16.1%) |